Prognosis in non-metastatic colorectal cancer: Multivariate evaluation of preoperative levels of six tumor markers in addition to clinical parameters

LaboratoriumsMedizin

Volumn 31, Issue 2, 2007, Pages 76-85

  Hofmann, Dominik ^a   Nagel, Dorothea ^a   Lau Werner, Ulla ^a   Wichmann, Matthias W ^a   Hornung, Hans Martin ^a   Stenman, Ulf H ^b   Schalhorn, Andreas ^a   Stieber, Petra ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CA 19 9; CA 242; CA 72 4; CEA; Colorectal cancer; hCG

Indexed keywords

CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; TREATMENT INDICATION;

EID: 34247137094     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2007.012     Document Type: Article

References (24)

1. Becker N. Epidemiologie kolorektaler Tumoren. Radiologe 2003;43:98-104.
2. Hermanek P. pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J Surg 1995;19:184-90.
3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
4. Henson DE, Fielding LP, Grignon DJ, Page DL, Hammond ME, Nash G, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch Pathol Lab Med 1995;119:1109-12.
5. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer 2000;88:1739-57.
6. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000;20:5195-8.
7. Carpelan-Holmstrom M, Haglund C, Lundin J, Jarvinen H, Roberts P. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer 1996;32A:1156-61.
8. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002;101:545-8.
9. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 1995;6:581-7.
10. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al. CYFRA 21-1. A new marker in lung cancer. Cancer 1993;72:707-13.
11. Alfthan H, Schroder J, Fraser R, Koskimies A, Halila H, Stenman UH. Choriogonadotropin and its beta subunit separated by hydrophobic-interaction chromatography and quantified in serum during pregnancy by time-resolved immunofluorometric assays. Clin Chem 1988;34:1758-62.
12. Collett D. Modelling survival data in medical research, 1st ed. London: Chapman & Hall, 1995.
13. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
14. Schumacher M, Hollander N, Sauerbrei W. Resampling and cross-validation techniques: a tool to reduce bias caused by model building? Stat Med 1997;16:2813-27.
15. Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol 2003;84:127-31.
16. Park YJ, Park KJ, Park JG, Lee KU, Choe KJ, Kim JP. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 1999;23:721-6.
17. Bosman FT. Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 1995;31A:1216-21.
18. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-27.
19. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467-81.
20. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997;185:55-9.
21. Carriquiry LA, Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999;42:921-9.
22. Behbehani AI, Al Sayer H, Farghaly M, Kanawati N, Mathew A, al Bader A, et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int J Biol Markers 2000;15:51-5.
23. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, et al. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Hepatogastroenterology 2003;50:696-9.
24. Lindmark G, Kressner U, Bergstrom R, Glimelius B. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer. Anticancer Res 1996;16:895-8.